Hologic (HOLX) 10-Q 2 Feb 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 30, 2023	Jan. 25, 2024
Cover [Abstract]
Title of 12(b) Security	Common Stock, $0.01 par value
Document Transition Report	false
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01752
Entity File Number	1-36214
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 30, 2023
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-28
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		234,731,521
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
City Area Code	(508)
Local Phone Number	263-2900
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive,
Entity Address, City or Town	Marlborough,
Entity Address, State or Province	MA
Trading Symbol	HOLX
Security Exchange Name	NASDAQ

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Revenues:
Product	$ 828.1	$ 886.3
Service and other	185	187.9
Revenues	1,013.1	1,074.2
Costs of revenues:
Product	307.2	296.2
Amortization, Cost of Goods Sold	45.5	55.6
Service and other	92.9	104.5
Gross profit	567.5	617.9
Operating expenses:
Research and development	66.8	74.8
Selling and marketing	148.9	163.5
General and administrative	111.8	108.5
Amortization of acquired intangible assets	13.3	7.6
Impairment of intangible asset	4.3	0
Contingent consideration - fair value adjustment	1.7	0
Restructuring charges	22.5	1.1
Operating expenses	369.3	355.5
Income from operations	198.2	262.4
Interest income	27.9	20.6
Interest expense	(26)	(28.1)
Other expense, net	(8.8)	(15.8)
Income before income taxes	191.3	239.1
Provision (benefit) for income taxes	(55.2)	51.7
Net income	$ 246.5	$ 187.4
Net income per common share:
Basic (in usd per share)	$ 1.03	$ 0.76
Diluted (in usd per share)	$ 1.03	$ 0.75
Weighted average number of shares outstanding:
Basic (in shares)	238,627	247,319
Diluted (in shares)	240,214	249,281

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 246.5	$ 187.4
Changes in foreign currency translation adjustment	43	113.8
Loss recognized in other comprehensive income	(14.2)	(2.9)
Other comprehensive income	28.8	110.9
Comprehensive income	$ 275.3	$ 298.3

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Tax	$ (4,500,000)	$ (0.9)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 1,932.1	$ 2,722.5
Accounts receivable, less reserves	670.9	625.6
Inventory	633.6	617.6
Prepaid Expense, Current	155.8	175.3
Prepaid Income Taxes-Current	101.8	31.6
Disposal Group, Including Discontinued Operation, Assets	0	11.9
Total current assets	3,494.2	4,184.5
Property, plant and equipment, net	527	517
Intangible assets, net	832.7	888.6
Goodwill	3,305.9	3,281.3
Other assets	309.7	267.9
Total assets	8,469.5	9,139.3
Current liabilities:
Current portion of long-term debt	37.4	287
Accounts payable	183.8	175.2
Accrued expenses	484	534.6
Deferred revenue	190.6	199.2
Finance lease obligations	3.2	3.1
Disposal Group, Including Discontinued Operation, Liabilities, Current	0	8.2
Total current liabilities	899	1,207.3
Long-term debt, net of current portion	2,522.7	2,531.2
Finance lease obligations, net of current portion	14.7	15.3
Deferred Income Tax Liabilities, Net	19.8	20.2
Deferred revenue, net of current portion	14.2	13.8
Other long-term liabilities	345.3	334.6
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 300,496 and 299,940 shares issued, respectively	3	3
Additional paid-in-capital	6,058.7	6,141.2
Retained earnings	2,302.8	2,056.3
Treasury stock, at cost – 65,952 and 58,231 shares, respectively	(3,591.9)	(3,036)
Accumulated other comprehensive loss	(118.8)	(147.6)
Total stockholders’ equity	4,653.8	5,016.9
Total liabilities and stockholders’ equity	$ 8,469.5	$ 9,139.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 30, 2023	Sep. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 10,000	$ 10,000
Preferred stock, authorized (in shares)	1,623,000,000	1,623,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 10,000	$ 10,000
Common stock, authorized (in shares)	750,000,000,000	750,000,000,000
Common stock, issued (in shares)	300,496,000,000	299,940,000,000
Treasury stock (in shares)	65,952,000,000	58,231,000,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Accelerated Share Repurchase Agreement	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Accelerated Share Repurchase Agreement	Retained Earnings	Total	Treasury Stock	Treasury Stock Accelerated Share Repurchase Agreement
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 4,876.2
Balance (in shares) at Sep. 24, 2022			298,533					51,401
Beginning balance at Sep. 24, 2022			$ 3	$ 6,042.6		$ 1,600.3	$ (238.2)	$ (2,531.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			267
Exercise of stock options				10.3
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			514
Vesting of restricted stock units, net of shares withheld for employee taxes	(23)			(23)
Common stock issued under the employee stock purchase plan (in shares)			171
Common stock issued under the employee stock purchase plan				10.2
Stock-based compensation expense				20.5
Net income	187.4
Other comprehensive income activity							110.9
Repurchase of common stock (in shares)								(1,539)
Repurchase of common stock								$ (100)
Net income	187.4
Balance (in shares) at Dec. 31, 2022			299,485					52,940
Ending balance at Dec. 31, 2022			$ 3	6,060.6		1,787.7	(127.3)	$ (2,631.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,092.5
Exercise of stock options (in shares)			173
Exercise of stock options				7.9
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			18
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.2)			(0.2)
Stock-based compensation expense				23.2
Net income	218.5
Other comprehensive income activity							8.9
Repurchase of common stock (in shares)								(626)
Repurchase of common stock								$ (50)
Net income	218.5
Balance (in shares) at Apr. 01, 2023			299,676					53,566
Ending balance at Apr. 01, 2023			$ 3	6,091.5		2,006.2	(118.4)	$ (2,681.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,300.8
Exercise of stock options (in shares)			64
Exercise of stock options				3.3
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			15
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.5)			(0.5)
Common stock issued under the employee stock purchase plan (in shares)			177
Common stock issued under the employee stock purchase plan				11.3
Stock-based compensation expense				16.9
Net income	(40.5)
Other comprehensive income activity							4.8
Repurchase of common stock (in shares)								(1,424)
Repurchase of common stock								$ (114.1)
Net income	(40.5)
Balance (in shares) at Jul. 01, 2023			299,932					54,990
Ending balance at Jul. 01, 2023			$ 3	6,122.5		1,965.7	(113.6)	$ (2,795.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,182
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			8
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.3)			(0.3)
Stock-based compensation expense				19
Net income	90.6
Other comprehensive income activity							(34)
Repurchase of common stock (in shares)								(3,241)
Repurchase of common stock								$ (240.4)
Net income	90.6
Balance (in shares) at Sep. 30, 2023			299,940					58,231
Ending balance at Sep. 30, 2023	5,016.9		$ 3	6,141.2		2,056.3	(147.6)	$ (3,036)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,016.9
Exercise of stock options (in shares)			124
Exercise of stock options				5
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			432
Vesting of restricted stock units, net of shares withheld for employee taxes				(16.2)
Stock-based compensation expense	28.7			28.7
Net income	246.5
Other comprehensive income activity							28.8
Repurchase of common stock (in shares)								(2,161)	5,560
Repurchase of common stock		$ (500)			$ (100)			$ (155.9)	$ (400)
Net income	246.5
Balance (in shares) at Dec. 30, 2023			300,496					65,952
Ending balance at Dec. 30, 2023	4,653.8		$ 3	$ 6,058.7		$ 2,302.8	$ (118.8)	$ (3,591.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 4,653.8

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023		Sep. 30, 2023		Apr. 01, 2023	Dec. 31, 2022
OPERATING ACTIVITIES
Net income	$ 246.5		$ 90.6		$ 218.5	$ 187.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	29.6					22.7
Amortization of acquired intangible assets	58.8					63.2
Stock-based compensation expense	28.7					20.5
Deferred income taxes	(17.6)					(26.2)
Intangible asset impairment charge	4.3					0
Other adjustments and non-cash items	27.5					29.1
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
Accounts receivable	(38.2)					(45)
Inventories	(13)					(47)
Prepaid income taxes	(70.1)					17.9
Prepaid expenses and other assets	2.6					26.2
Accounts payable	7.2					1.5
Accrued expenses and other liabilities	(35.7)					0.8
Deferred revenue	(10.6)					2.3
Net cash provided by operating activities	220					253.4
INVESTING ACTIVITIES
Sale of business, net of cash disposed	(31.3)					0
Capital expenditures	(22.7)					(15.8)
Increase in equipment under customer usage agreements	(15.3)					(13.3)
Payments to Acquire Equity Method Investments	34.5					10
Payments for (Proceeds from) Other Investing Activities	(0.4)					(1.9)
Net cash used in investing activities	(104.2)					(41)
FINANCING ACTIVITIES
Repayment of long-term debt	(259.4)					(3.8)
Payment of deferred acquisition consideration	0					(0.8)
Repurchase of common stock	(676.8)					(100)
Proceeds from issuance of common stock pursuant to employee stock plans	9.5					15.1
Payment of minimum tax withholdings on net share settlements of equity awards	(16.2)					(23)
Payments under finance lease obligations	(0.9)					(1)
Net cash used in financing activities	(943.8)					(113.5)
Effect of exchange rate changes on cash and cash equivalents	4.4					2.9
Net (decrease) increase in cash and cash equivalents	(823.6)					101.8
Cash and cash equivalents, beginning of period*	2,755.7	[1]			$ 2,441.3	2,339.5	[1]
Cash and cash equivalents, end of period	$ 1,932.1		$ 2,755.7	[1]		$ 2,441.3
[1]Includes $33.2 million of cash recorded in assets held-for-sale - current assets as of September 30, 2023.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 28, 2023
Disposed of by Sale | SSI Ultrasound Imaging Business
Disposal Group, Including Discontinued Operation, Cash	$ 33.2	$ 33.2

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 30, 2023
Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 30, 2023 included in the Company’s annual report on Form 10-K filed with the SEC on November 21, 2023. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 30, 2023 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 28, 2024. Fiscal 2023 was a 53-week fiscal year, and the additional week was included in the first quarter of fiscal 2023 consistent with the Company’s historical fiscal calendar. Subsequent Events Consideration

Leases

Leases	3 Months Ended
	Dec. 30, 2023
Leases [Abstract]
Leases	Leases Lessor Activity - Leases where Hologic is the Lessor
Leases	Leases Lessor Activity - Leases where Hologic is the Lessor

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Dec. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in derivative instruments comprised of interest rate swaps and forward foreign currency contracts, which are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has contingent consideration liabilities that are recorded at fair value, which is based on Level 3 inputs. The contingent consideration liability as of December 30, 2023 and December 31, 2022 was primarily related to the Acessa acquisition. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 30, 2023: Fair Value at Reporting Date Using Balance as of December 30, 2023 Quoted Prices in Significant Significant Assets: Interest rate swaps $ 8.2 $ — $ 8.2 $ — Total $ 8.2 $ — $ 8.2 $ — Liabilities: Contingent consideration $ 3.7 $ — $ — $ 3.7 Forward foreign currency contracts 4.1 — 4.1 — Total $ 7.8 $ — $ 4.1 $ 3.7 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three month periods ended December 30, 2023 and December 31, 2022 were as follows: Three Month Ended December 30, 2023 December 31, 2022 Balance at beginning of period $ 2.0 $ 23.4 Contingent consideration recorded at acquisition — — Fair value adjustments 1.7 — Payments — — Balance at end of period $ 3.7 $ 23.4 Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, including property, plant and equipment, intangible assets, and goodwill. During the first quarter of fiscal 2024, the Company recorded a $12.5 million impairment charge for right of use lease assets related to the expected closure of facilities in the Diagnostics division (see Note 8 for further discussion). In addition, during the first quarter of fiscal 2024, the Company recorded a $4.3 million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the fair value of this asset to $22.4 million. There were no other remeasurements in the three months ended December 30, 2023 and December 31, 2022. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate swaps and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. Amounts outstanding under the Company’s 2021 Credit Agreement of $1.2 billion aggregate principal as of December 30, 2023 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) and 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) had fair values of $386.3 million and $858.0 million, respectively, as of December 30, 2023 based on their trading prices, representing a Level 1 measurement. Refer to Note 9 for the carrying amounts of the various components of the Company’s debt.

Business Combinations

Business Combinations	3 Months Ended
	Dec. 30, 2023
Business Combinations [Abstract]
Business Combinations	Business Combinations Fiscal 2023 Acquisitions JW Medical On July 3, 2023, the Company completed the acquisition of assets from JW Medical Corporation (“JW Medical”) for a purchase price of $6.7 million. JW Medical was a long-standing distributor of the Company’s Breast Health products in South Korea. The majority of the purchase price was allocated to a customer relationship intangible asset with a useful life of 5 years. Normedi On April 3, 2023, the Company completed the acquisition of Normedi Nordic AS (“Normedi”) for a purchase price of $7.7 million. Normedi was a long-standing distributor of the Company’s Surgical products in the Nordics region of Europe. The purchase price includes $1.1 million for contingent consideration based on incremental revenue growth over a 2-year measurement period. The Company allocated $3.0 million of the purchase price to a customer relationships intangible asset with a useful life of 5 years, and the excess of the purchase price over the net assets acquired was recorded to goodwill. Contingent Consideration The Company’s contingent consideration liability is primarily related to its acquisition of Acessa Health, Inc. (“Acessa”), which was acquired in August 2020. Acessa developed the ProVu laparoscopic radiofrequency ablation system. The Company estimated the fair value of this liability to be $81.8 million as of the acquisition date. The contingent payments were based on a multiple of annual incremental revenue growth over a three-year period ending annually in December of each of 2021, 2022, and 2023. There was no maximum earnout. Pursuant to ASC 805, Business Combinations (ASC 805), the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acessa, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter the Company was required to remeasure the fair value of the liability as assumptions change, and such adjustments were recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820, Fair Value Measurements . This fair value measurement was directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth were higher or lower than the estimates within the fair value measurement, the Company would record additional charges or gains. During the three months ended December 30, 2023, the third and final measurement period was completed, and the Company recorded a loss of $1.7 million to increase the contingent consideration liability to fair value based on actual revenue results in the final earn-out period. As of December 30, 2023, the contingent consideration liability related to Acessa was $2.6 million and the payment is expected to be made during the second quarter of fiscal 2024.

Strategic Investment

Strategic Investment	3 Months Ended
	Dec. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Strategic Investment	Strategic Investment Maverix Medical On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc. (“KKR Comet”), to form a legal entity to develop and acquire innovative technologies and commercial operations within the lung cancer space. The new entity, named Maverix Medical LLC (“Maverix”), will be managed by Ajax Health. As part of this strategic investment, the Company contributed $24.5 million in return for 45% ownership in the Class A Common units of Maverix, and both the Company and KKR Comet have committed to make additional capital contributions in proportion to the ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810, Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that this investment should be accounted for under the equity method, which requires the Company to record its proportional share of the entity’s net income (loss). This investment is recorded within Other assets in the Consolidated Balance Sheets, and the Company’s proportionate share of Maverix’s loss for the three months ended December 30, 2023 was immaterial.

Disposition

Disposition	3 Months Ended
	Dec. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Disposition	Disposition Sale of SuperSonic Imagine Ultrasound Imaging Business On September 29, 2023, the Company executed an agreement to sell its SSI ultrasound imaging business to SSH Holdings Limited for a sales price of $1.9 million in cash. Under the terms of the contract, the Company agreed to fund the SSI business with $33.2 million of cash. The sale was completed on October 3, 2023. The Company also agreed to provide certain transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset group met the criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, the Company recorded a charge of $51.7 million in the fourth quarter of fiscal 2023 to record the asset group to its fair value less costs to sell pursuant to ASC 360, Property, Plant and Equipment-Impairment or Disposal of Long-Lived Assets . The assets and liabilities of the disposed business at the date of disposition were as follows: Assets: Cash $ 33.2 Accounts receivable 4.5 Inventory 16.2 Prepaid expenses and other assets 8.6 Valuation allowance (50.6) Total assets disposed of $ 11.9 Liabilities: Accounts payable $ 3.1 Accrued expenses 5.1 Total liabilities disposed of $ 8.2 The valuation allowance of $50.6 million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company has determined that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company’s operations and financial results.

Trade Receivables and Allowance

Trade Receivables and Allowance for Credit Losses	3 Months Ended
	Dec. 30, 2023
Receivables [Abstract]
Trade Receivables and Allowance for Credit Losses	Trade Receivables and Allowance for Credit Losses The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of December 30, 2023 compared to December 31, 2022: Balance at Credit Loss Write-offs, Balance at Three Months Ended December 30, 2023 $ 38.5 $ 4.9 $ (0.3) $ 43.1 December 31, 2022 $ 37.7 $ 1.2 $ 0.2 $ 39.1

Restructuring

Restructuring	3 Months Ended
	Dec. 30, 2023
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure	(8) Restructuring During the first quarter of fiscal 2024, as a result of a change in strategy for a certain business within Diagnostics, including the discontinuation of the sale of certain products and expected closure of facilities, the Company determined certain fixed assets lives should be shortened and lease assets were impaired at the affected facilities. As such, the Company recorded accelerated depreciation of $7.2 million and a lease asset impairment charge of $12.5 million. The Company has initiated discussions with the respective Works Councils. In addition, the Company recorded the minimum statutory severance benefit for the affected employee groups of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits . The Company expects total severance benefits related to this action will be approximately $4.0 million to $8.0 million. This action is expected to be completed by the end of calendar 2024. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company’s Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions are also transferring to the Newark, Delaware and Marlborough, Massachusetts facilities. The transition is expected to be completed by the third quarter of fiscal 2025. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420, Exit or Disposal Cost Obligations

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	3 Months Ended
	Dec. 30, 2023
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: December 30, September 30, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 37.4 $ 287.0 Total current debt obligations $ 37.4 $ 287.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,186.4 1,195.6 2028 Senior Notes 397.0 396.8 2029 Senior Notes 939.3 938.8 Total long-term debt obligations $ 2,522.7 $ 2,531.2 Total debt obligations $ 2,560.1 $ 2,818.2 2021 Credit Agreement On September 27, 2021, the Company refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the “2018 Credit Agreement”) by entering into a Refinancing Amendment (the “2021 Credit Agreement”). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (“SOFR”), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a $1.5 billion secured term loan facility (the “2021 Term Loan”) and a $2.0 billion revolving credit facility (the “2021 Revolver”). As of December 30, 2023, the principal amount outstanding under the 2021 Term Loan was $1.2 billion, and the interest rate was 6.46% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a $250.0 million voluntary prepayment on the 2021 Term Loan. Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended December 30, 2023 December 31, 2022 Interest expense $ 22.6 $ 20.4 Weighted average interest rate 6.44 % 4.63 % Interest rate at end of period 6.46 % 5.43 % The Company’s effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on $1.0 billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on $500 million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving $9.7 million and $6.6 million during the three months ended December 30, 2023 and December 31, 2022, respectively, which was recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of December 30, 2023, the Company was in compliance with these covenants. 2028 Senior Notes As of December 30, 2023, the Company had 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) outstanding in the aggregate principal balance of $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 1, 2028. 2029 Senior Notes As of December 30, 2023, the Company had 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 15, 2029. Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Interest Rate December 30, 2023 December 31, 2022 2028 Senior Notes 4.625 % 4.8 5.2 2029 Senior Notes 3.250 % 8.2 8.9 Total $ 13.0 $ 14.1

Derivatives

Derivatives	3 Months Ended
	Dec. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Interest Rate Swaps - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (“AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform , in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was $1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on $1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract ended during the first quarter of fiscal 2024 and as a result the fair value of this derivative was $0.0 million as of December 30, 2023. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is $500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $500 million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of $8.2 million as of December 30, 2023. Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company’s cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts; however, the Company may seek to apply hedge accounting in future scenarios. As of December 30, 2023 the notional amount was $282.3 million. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three months ended December 30, 2023 and December 31, 2022, respectively, were as follows: Three Months Ended December 30, 2023 December 31, 2022 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 1.3 $ (2.4) Foreign currency option contracts — (0.2) $ 1.3 $ (2.6) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ (12.5) $ (13.8) Foreign currency option contracts — (8.3) $ (12.5) $ (22.1) Amount of gain (loss) recognized in income Total $ (11.2) $ (24.7) Financial Instrument Presentation The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of December 30, 2023: Balance Sheet Location December 30, 2023 September 30, 2023 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 6.0 $ 16.2 Interest rate swap contracts Other assets 2.2 10.7 $ 8.2 $ 26.9 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ — $ 8.4 $ — $ 8.4 Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 4.1 $ — The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended December 30, 2023 December 31, 2022 Amount of (loss) gain recognized in other comprehensive income, net of taxes: Interest rate swaps $ (14.2) $ (2.9) Total $ (14.2) $ (2.9)

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies Litigation and Related Matters On November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of 84 plaintiffs, one pending in Massachusetts state court, which has set a tentative November 2025 trial date, and the remainder in United States District Court for the District of Massachusetts. which has not set a trial date. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the outcome of this matter. The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it, the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies (ASC 450). Legal costs are expensed as incurred.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Dec. 30, 2023
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 30, December 31, Basic weighted average common shares outstanding 238,627 247,319 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,587 1,962 Diluted weighted average common shares outstanding 240,214 249,281 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 2,046 1,631

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended December 30, December 31, Cost of revenues $ 2.8 $ 2.9 Research and development 3.2 3.4 Selling and marketing 3.2 3.3 General and administrative 19.5 10.9 $ 28.7 $ 20.5 The Company granted options to purchase 0.5 million and 0.5 million shares of the Company’s common stock during the three months ended December 30, 2023 and December 31, 2022, respectively, with weighted-average exercise prices of $71.93 and $74.26, respectively. There were 4.5 million options outstanding at December 30, 2023 with a weighted-average exercise price of $54.20. The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 30, December 31, Risk-free interest rate 4.4 % 4.3 % Expected volatility 33.4 % 33.9 % Expected life (in years) 4.8 4.8 Dividend yield — — Weighted average fair value of options granted $ 24.93 $ 25.81 The Company granted 0.7 million and 0.6 million restricted stock units (“RSUs”) during the three months ended December 30, 2023 and December 31, 2022, respectively, with weighted-average grant date fair values of $71.90 and $74.30 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (“PSUs”) during the three months ended December 30, 2023 and December 31, 2022, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $71.92 and $74.35 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period, provided that the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1 million of FCF PSUs based on a three-year cumulative free cash flow measure (“FCF PSUs”) to members of its senior management team, which had a grant date fair value of $71.92 and $74.35 per unit during the three months ended December 30, 2023 and December 31, 2022, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of the three-year measurement period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the probable number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (“MSUs”) to members of its senior management team during the three months ended December 30, 2023 and December 31, 2022, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $88.06 and $97.91 per share using the Monte Carlo simulation model in fiscal 2024 and 2023, respectively. The MSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At December 30, 2023, there was 1.7 million in aggregate unvested RSUs, PSUs, FCF PSUs and MSUs outstanding. At December 30, 2023, there was $17.7 million and $86.7 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.3 and 2.0 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Dec. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information December 30, September 30, Inventories Raw materials $ 264.2 $ 238.6 Work-in-process 60.2 66.3 Finished goods 309.2 312.7 $ 633.6 $ 617.6 Property, plant and equipment Equipment $ 380.6 $ 380.0 Equipment under customer usage agreements 520.6 508.1 Building and improvements 240.6 230.0 Leasehold improvements 46.0 44.4 Land 41.2 41.1 Furniture and fixtures 19.9 19.2 Finance lease right-of-use asset 8.5 8.2 $ 1,257.4 $ 1,231.0 Less – accumulated depreciation and amortization (730.4) (714.0) $ 527.0 $ 517.0

Business Segments and Geographi

Business Segments and Geographic Information	3 Months Ended
	Dec. 30, 2023
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three months ended December 30, 2023 and December 31, 2022. Segment information is as follows: Three Months Ended December 30, December 31, Total revenues: Diagnostics $ 447.8 $ 559.3 Breast Health 377.7 334.2 GYN Surgical 162.2 154.1 Skeletal Health 25.4 26.6 $ 1,013.1 $ 1,074.2 Income from operations: Diagnostics $ 49.4 $ 151.1 Breast Health 102.2 60.5 GYN Surgical 43.2 48.8 Skeletal Health 3.4 2.0 $ 198.2 $ 262.4 Depreciation and amortization: Diagnostics $ 65.9 $ 59.9 Breast Health 10.3 13.6 GYN Surgical 12.0 12.3 Skeletal Health 0.2 0.1 $ 88.4 $ 85.9 Capital expenditures: Diagnostics $ 24.2 $ 15.9 Breast Health 9.3 7.2 GYN Surgical 4.2 3.9 Skeletal Health 0.1 0.1 Corporate 0.2 2.0 $ 38.0 $ 29.1 December 30, September 30, Identifiable assets: Diagnostics $ 2,570.1 $ 2,596.4 Breast Health 1,234.1 1,170.1 GYN Surgical 1,450.1 1,455.4 Skeletal Health 30.3 33.7 Corporate 3,184.9 3,883.7 $ 8,469.5 $ 9,139.3 The Company had no customers that represented greater than 10% of consolidated revenues during the three months ended December 30, 2023 and December 31, 2022. The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 30, December 31, United States 74.4 % 76.7 % Europe 14.1 % 13.7 % Asia-Pacific 6.3 % 5.9 % Rest of World 5.2 % 3.7 % 100.0 % 100.0 %

Income Taxes

Income Taxes	3 Months Ended
	Dec. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes , each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. The Company’s effective tax rate for the three months ended December 30, 2023 was a benefit of 28.9% compared to a provision of 21.6% for the corresponding period in the prior year. The effective tax rate for the three months ended December 30, 2023 was lower than the U.S. statutory tax rate primarily due to a $107.2 million discrete tax benefit related to a worthless stock deduction on the investment in one of the Company’s international subsidiaries. The effective tax rate for the three months ended December 31, 2022 was higher than the U.S. statutory tax rate primarily due to income tax reserves, the global intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by our international subsidiaries, which are taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits. Non-Income Tax Matters The Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets Intangible assets consisted of the following: Description As of December 30, 2023 As of September 30, 2023 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,419.7 $ 3,698.9 $ 4,411.0 $ 3,649.5 In-process research and development 22.4 — 25.7 — Customer relationships 602.6 559.6 600.0 550.6 Trade names 254.1 219.0 253.6 212.8 Total acquired intangible assets $ 5,298.8 $ 4,477.5 $ 5,290.3 $ 4,412.9 Internal-use software 24.9 18.7 24.0 17.8 Capitalized software embedded in products 28.4 23.2 27.7 22.7 Total intangible assets $ 5,352.1 $ 4,519.4 $ 5,342.0 $ 4,453.4 The estimated remaining amortization expense of the Company’s acquired intangible assets as of December 30, 2023 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2024 $ 151.5 Fiscal 2025 $ 188.5 Fiscal 2026 $ 158.6 Fiscal 2027 $ 71.5 Fiscal 2028 $ 68.5 During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag Oy acquisition for impairment. The Company determined the fair value of this indefinite lived asset utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trademark intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million.

Product Warranties

Product Warranties	3 Months Ended
	Dec. 30, 2023
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Provisions Settlements/ Balance at Three Months Ended: December 30, 2023 $ 8.3 $ 2.9 $ (2.1) $ 9.1 December 31, 2022 $ 8.0 $ 2.6 $ (2.2) $ 8.4

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Dec. 30, 2023
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended December 30, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (168.0) $ 0.3 $ 20.1 $ (147.6) Other comprehensive income (loss) before reclassifications 43.0 — (14.2) 28.8 Ending Balance $ (125.0) $ 0.3 $ 5.9 $ (118.8) Three Months Ended December 31, 2022 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (267.2) $ (0.3) $ 29.3 $ (238.2) Other comprehensive income (loss) before reclassifications 113.8 — (2.9) $ 110.9 Ending Balance $ (153.4) $ (0.3) $ 26.4 $ (127.3)

Share Repurchase

Share Repurchase	3 Months Ended
	Dec. 30, 2023
Equity [Abstract]
Share Repurchase	Share Repurchase On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous $1.0 billion authorization. During the three months ended December 30, 2023 and December 31, 2022, the Company repurchased 2.2 million and 1.5 million shares of its common stock under the authorization for total consideration of $150.0 million and $100.0 million, respectively. As of December 30, 2023, $348.6 million remained available under this authorization. On November 6, 2023, the Board of Directors authorized the Company to repurchase up to $500 million of the Company’s outstanding shares pursuant to an accelerated share repurchase (“ASR”) agreement. On November 15, 2023, the Company executed the ASR agreement with Goldman Sachs & Co. (“Goldman Sachs”) pursuant to which the Company agreed to repurchase $500 million of the Company’s common stock. In connection with the launch of the ASR, on November 17, 2023, the Company paid Goldman Sachs an aggregate of $500 million and received approximately 5.6 million shares of the Company’s common stock, representing 80% of the transaction value based on the Company’s closing share price on November 14, 2023. The final number of shares to be received under the ASR agreement will be determined upon completion of the transaction and will be based on the total transaction value and the volume-weighted average share price of the Company’s common stock during the term of the transaction. Final settlement of the transaction is expected to be completed in the second quarter of fiscal 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Sep. 30, 2023	Jul. 01, 2023	Apr. 01, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 246.5	$ 90.6	$ (40.5)	$ 218.5	$ 187.4

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Revenue from Contract with Cust

Revenue from Contract with Customer (Policies)	3 Months Ended
	Dec. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	(2) Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company’s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended December 30, 2023 Business ( in millions ) United States International Total Diagnostics: Cytology & Perinatal $ 69.8 $ 50.2 $ 120.0 Molecular Diagnostics 247.6 72.2 319.8 Blood Screening 8.0 — 8.0 Total $ 325.4 $ 122.4 $ 447.8 Breast Health: Breast Imaging $ 228.4 $ 73.0 $ 301.4 Interventional Breast Solutions 61.1 15.2 76.3 Total $ 289.5 $ 88.2 $ 377.7 GYN Surgical $ 125.1 $ 37.1 $ 162.2 Skeletal Health $ 13.7 $ 11.7 $ 25.4 $ 753.7 $ 259.4 $ 1,013.1 Three Months Ended December 31, 2022 Business (in millions) United States International Total Diagnostics: Cytology & Perinatal $ 78.2 $ 48.6 $ 126.8 Molecular Diagnostics 328.2 97.0 425.2 Blood Screening 7.3 — 7.3 Total $ 413.7 $ 145.6 $ 559.3 Breast Health: Breast Imaging $ 212.2 $ 52.2 $ 264.4 Interventional Breast Solutions 57.8 12.0 69.8 Total $ 270.0 $ 64.2 $ 334.2 GYN Surgical $ 123.1 $ 31.0 $ 154.1 Skeletal Health $ 16.8 $ 9.8 $ 26.6 $ 823.6 $ 250.6 $ 1,074.2 Three Months Ended Geographic Regions ( in millions ) December 30, 2023 December 31, 2022 United States $ 753.7 $ 823.6 Europe 142.8 147.4 Asia-Pacific 63.8 63.8 Rest of World 52.8 39.4 $ 1,013.1 $ 1,074.2 The following table provides revenue recognized by source: Three Months Ended Revenue by type (in millions) December 30, 2023 December 31, 2022 Disposables $ 628.9 $ 727.8 Capital equipment, components and software 199.2 158.5 Service 178.8 183.3 Other 6.2 4.6 $ 1,013.1 $ 1,074.2 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Revenue from laboratory testing services, which is generated by the Company’s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors. Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company’s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Company’s financial statements. Remaining Performance Obligations As of December 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $808.9 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company’s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 37% of this amount as revenue in fiscal 2024, 33% in fiscal 2025, 18% in fiscal 2026, 8% in fiscal 2027, and 4% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of $64.4 million and $66.8 million in the three months ended December 30, 2023 and December 31, 2022, respectively, that was included in the contract liability balance at September 30, 2023 and September 24, 2022, respectively. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Dec. 30, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended December 30, 2023 Business ( in millions ) United States International Total Diagnostics: Cytology & Perinatal $ 69.8 $ 50.2 $ 120.0 Molecular Diagnostics 247.6 72.2 319.8 Blood Screening 8.0 — 8.0 Total $ 325.4 $ 122.4 $ 447.8 Breast Health: Breast Imaging $ 228.4 $ 73.0 $ 301.4 Interventional Breast Solutions 61.1 15.2 76.3 Total $ 289.5 $ 88.2 $ 377.7 GYN Surgical $ 125.1 $ 37.1 $ 162.2 Skeletal Health $ 13.7 $ 11.7 $ 25.4 $ 753.7 $ 259.4 $ 1,013.1 Three Months Ended December 31, 2022 Business (in millions) United States International Total Diagnostics: Cytology & Perinatal $ 78.2 $ 48.6 $ 126.8 Molecular Diagnostics 328.2 97.0 425.2 Blood Screening 7.3 — 7.3 Total $ 413.7 $ 145.6 $ 559.3 Breast Health: Breast Imaging $ 212.2 $ 52.2 $ 264.4 Interventional Breast Solutions 57.8 12.0 69.8 Total $ 270.0 $ 64.2 $ 334.2 GYN Surgical $ 123.1 $ 31.0 $ 154.1 Skeletal Health $ 16.8 $ 9.8 $ 26.6 $ 823.6 $ 250.6 $ 1,074.2 Three Months Ended Geographic Regions ( in millions ) December 30, 2023 December 31, 2022 United States $ 753.7 $ 823.6 Europe 142.8 147.4 Asia-Pacific 63.8 63.8 Rest of World 52.8 39.4 $ 1,013.1 $ 1,074.2 The following table provides revenue recognized by source: Three Months Ended Revenue by type (in millions) December 30, 2023 December 31, 2022 Disposables $ 628.9 $ 727.8 Capital equipment, components and software 199.2 158.5 Service 178.8 183.3 Other 6.2 4.6 $ 1,013.1 $ 1,074.2

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 30, 2023: Fair Value at Reporting Date Using Balance as of December 30, 2023 Quoted Prices in Significant Significant Assets: Interest rate swaps $ 8.2 $ — $ 8.2 $ — Total $ 8.2 $ — $ 8.2 $ — Liabilities: Contingent consideration $ 3.7 $ — $ — $ 3.7 Forward foreign currency contracts 4.1 — 4.1 — Total $ 7.8 $ — $ 4.1 $ 3.7 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three month periods ended December 30, 2023 and December 31, 2022 were as follows: Three Month Ended December 30, 2023 December 31, 2022 Balance at beginning of period $ 2.0 $ 23.4 Contingent consideration recorded at acquisition — — Fair value adjustments 1.7 — Payments — — Balance at end of period $ 3.7 $ 23.4

Disposition (Tables)

Disposition (Tables)	3 Months Ended
	Dec. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Income from Operation of Disposed Business	The assets and liabilities of the disposed business at the date of disposition were as follows: Assets: Cash $ 33.2 Accounts receivable 4.5 Inventory 16.2 Prepaid expenses and other assets 8.6 Valuation allowance (50.6) Total assets disposed of $ 11.9 Liabilities: Accounts payable $ 3.1 Accrued expenses 5.1 Total liabilities disposed of $ 8.2

Trade Receivables and Allowan_2

Trade Receivables and Allowance for Credit Losses (Tables)	3 Months Ended
	Dec. 30, 2023
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following is a rollforward of the allowance for credit losses as of December 30, 2023 compared to December 31, 2022: Balance at Credit Loss Write-offs, Balance at Three Months Ended December 30, 2023 $ 38.5 $ 4.9 $ (0.3) $ 43.1 December 31, 2022 $ 37.7 $ 1.2 $ 0.2 $ 39.1

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	3 Months Ended
	Dec. 30, 2023
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: December 30, September 30, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 37.4 $ 287.0 Total current debt obligations $ 37.4 $ 287.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,186.4 1,195.6 2028 Senior Notes 397.0 396.8 2029 Senior Notes 939.3 938.8 Total long-term debt obligations $ 2,522.7 $ 2,531.2 Total debt obligations $ 2,560.1 $ 2,818.2
Schedule of Line of Credit Facilities	Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended December 30, 2023 December 31, 2022 Interest expense $ 22.6 $ 20.4 Weighted average interest rate 6.44 % 4.63 % Interest rate at end of period 6.46 % 5.43 %
Schedule Of Interest Expense Under Convertible Notes	Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Interest Rate December 30, 2023 December 31, 2022 2028 Senior Notes 4.625 % 4.8 5.2 2029 Senior Notes 3.250 % 8.2 8.9 Total $ 13.0 $ 14.1

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Dec. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	Three Months Ended December 30, 2023 December 31, 2022 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 1.3 $ (2.4) Foreign currency option contracts — (0.2) $ 1.3 $ (2.6) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ (12.5) $ (13.8) Foreign currency option contracts — (8.3) $ (12.5) $ (22.1) Amount of gain (loss) recognized in income Total $ (11.2) $ (24.7)
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of December 30, 2023: Balance Sheet Location December 30, 2023 September 30, 2023 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 6.0 $ 16.2 Interest rate swap contracts Other assets 2.2 10.7 $ 8.2 $ 26.9 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ — $ 8.4 $ — $ 8.4 Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 4.1 $ —
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended December 30, 2023 December 31, 2022 Amount of (loss) gain recognized in other comprehensive income, net of taxes: Interest rate swaps $ (14.2) $ (2.9) Total $ (14.2) $ (2.9)

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Dec. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 30, December 31, Basic weighted average common shares outstanding 238,627 247,319 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,587 1,962 Diluted weighted average common shares outstanding 240,214 249,281 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 2,046 1,631

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended December 30, December 31, Cost of revenues $ 2.8 $ 2.9 Research and development 3.2 3.4 Selling and marketing 3.2 3.3 General and administrative 19.5 10.9 $ 28.7 $ 20.5
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 30, December 31, Risk-free interest rate 4.4 % 4.3 % Expected volatility 33.4 % 33.9 % Expected life (in years) 4.8 4.8 Dividend yield — — Weighted average fair value of options granted $ 24.93 $ 25.81

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	December 30, September 30, Inventories Raw materials $ 264.2 $ 238.6 Work-in-process 60.2 66.3 Finished goods 309.2 312.7 $ 633.6 $ 617.6
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment $ 380.6 $ 380.0 Equipment under customer usage agreements 520.6 508.1 Building and improvements 240.6 230.0 Leasehold improvements 46.0 44.4 Land 41.2 41.1 Furniture and fixtures 19.9 19.2 Finance lease right-of-use asset 8.5 8.2 $ 1,257.4 $ 1,231.0 Less – accumulated depreciation and amortization (730.4) (714.0) $ 527.0 $ 517.0

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	3 Months Ended
	Dec. 30, 2023
Segment Reporting [Abstract]
Segment Information	egment information is as follows: Three Months Ended December 30, December 31, Total revenues: Diagnostics $ 447.8 $ 559.3 Breast Health 377.7 334.2 GYN Surgical 162.2 154.1 Skeletal Health 25.4 26.6 $ 1,013.1 $ 1,074.2 Income from operations: Diagnostics $ 49.4 $ 151.1 Breast Health 102.2 60.5 GYN Surgical 43.2 48.8 Skeletal Health 3.4 2.0 $ 198.2 $ 262.4 Depreciation and amortization: Diagnostics $ 65.9 $ 59.9 Breast Health 10.3 13.6 GYN Surgical 12.0 12.3 Skeletal Health 0.2 0.1 $ 88.4 $ 85.9 Capital expenditures: Diagnostics $ 24.2 $ 15.9 Breast Health 9.3 7.2 GYN Surgical 4.2 3.9 Skeletal Health 0.1 0.1 Corporate 0.2 2.0 $ 38.0 $ 29.1 December 30, September 30, Identifiable assets: Diagnostics $ 2,570.1 $ 2,596.4 Breast Health 1,234.1 1,170.1 GYN Surgical 1,450.1 1,455.4 Skeletal Health 30.3 33.7 Corporate 3,184.9 3,883.7 $ 8,469.5 $ 9,139.3
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 30, December 31, United States 74.4 % 76.7 % Europe 14.1 % 13.7 % Asia-Pacific 6.3 % 5.9 % Rest of World 5.2 % 3.7 % 100.0 % 100.0 %

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of December 30, 2023 As of September 30, 2023 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,419.7 $ 3,698.9 $ 4,411.0 $ 3,649.5 In-process research and development 22.4 — 25.7 — Customer relationships 602.6 559.6 600.0 550.6 Trade names 254.1 219.0 253.6 212.8 Total acquired intangible assets $ 5,298.8 $ 4,477.5 $ 5,290.3 $ 4,412.9 Internal-use software 24.9 18.7 24.0 17.8 Capitalized software embedded in products 28.4 23.2 27.7 22.7 Total intangible assets $ 5,352.1 $ 4,519.4 $ 5,342.0 $ 4,453.4
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense of the Company’s acquired intangible assets as of December 30, 2023 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2024 $ 151.5 Fiscal 2025 $ 188.5 Fiscal 2026 $ 158.6 Fiscal 2027 $ 71.5 Fiscal 2028 $ 68.5 During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag Oy acquisition for impairment. The Company determined the fair value of this indefinite lived asset utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trademark intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million.

Product Warranties (Tables)

Product Warranties (Tables)	3 Months Ended
	Dec. 30, 2023
Guarantees [Abstract]
Product Warranty Activity	Product warranty activity was as follows: Balance at Provisions Settlements/ Balance at Three Months Ended: December 30, 2023 $ 8.3 $ 2.9 $ (2.1) $ 9.1 December 31, 2022 $ 8.0 $ 2.6 $ (2.2) $ 8.4

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Dec. 30, 2023
Accumulated Other Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended December 30, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (168.0) $ 0.3 $ 20.1 $ (147.6) Other comprehensive income (loss) before reclassifications 43.0 — (14.2) 28.8 Ending Balance $ (125.0) $ 0.3 $ 5.9 $ (118.8) Three Months Ended December 31, 2022 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (267.2) $ (0.3) $ 29.3 $ (238.2) Other comprehensive income (loss) before reclassifications 113.8 — (2.9) $ 110.9 Ending Balance $ (153.4) $ (0.3) $ 26.4 $ (127.3)

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenues	$ 1,013.1	$ 1,074.2
United States
Disaggregation of Revenue [Line Items]
Revenues	753.7	823.6
International
Disaggregation of Revenue [Line Items]
Revenues	259.4	250.6
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	447.8	559.3
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	325.4	413.7
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	122.4	145.6
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	120	126.8
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	69.8	78.2
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	50.2	48.6
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	319.8	425.2
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	247.6	328.2
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	72.2	97
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	8	7.3
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	8	7.3
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	377.7	334.2
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	289.5	270
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	88.2	64.2
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	301.4	264.4
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	228.4	212.2
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	73	52.2
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	76.3	69.8
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	61.1	57.8
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	15.2	12
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	162.2	154.1
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	125.1	123.1
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	37.1	31
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	25.4	26.6
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	13.7	16.8
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 11.7	$ 9.8

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenues	$ 1,013.1	$ 1,074.2
United States
Disaggregation of Revenue [Line Items]
Revenues	753.7	823.6
Europe
Disaggregation of Revenue [Line Items]
Revenues	142.8	147.4
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	63.8	63.8
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 52.8	$ 39.4

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenues	$ 1,013.1	$ 1,074.2
Contract with Customer, Liability, Revenue Recognized	64.4	66.8
Disposables
Disaggregation of Revenue [Line Items]
Revenues	628.9	727.8
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	199.2	158.5
Service
Disaggregation of Revenue [Line Items]
Revenues	178.8	183.3
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 6.2	$ 4.6

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 808.9
Contract with Customer, Liability, Revenue Recognized	$ 64.4	$ 66.8

Revenue - Remaining Performance

Revenue - Remaining Performance Obligation (Details)	Dec. 30, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	37%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	33%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	18%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	8%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	4%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	3 Months Ended
	Dec. 30, 2023
Leases [Abstract]
Lease revenue as a percentage of total (percentage)	0.03

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) $ in Millions	Dec. 30, 2023 USD ($)
Assets:
Total	$ 8.2
Liabilities:
Total	7.8
Interest rate swap
Assets:
Total	8.2
Contingent consideration
Liabilities:
Total	3.7
Forward foreign currency contracts
Liabilities:
Total	4.1
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Total	0
Liabilities:
Total	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest rate swap
Assets:
Total	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Contingent consideration
Liabilities:
Total	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts
Liabilities:
Total	0
Significant Other Observable Inputs (Level 2)
Assets:
Total	8.2
Liabilities:
Total	4.1
Significant Other Observable Inputs (Level 2) | Interest rate swap
Assets:
Total	8.2
Significant Other Observable Inputs (Level 2) | Contingent consideration
Liabilities:
Total	0
Significant Other Observable Inputs (Level 2) | Forward foreign currency contracts
Liabilities:
Total	4.1
Significant Unobservable Inputs (Level 3)
Assets:
Total	0
Liabilities:
Total	3.7
Significant Unobservable Inputs (Level 3) | Interest rate swap
Assets:
Total	0
Significant Unobservable Inputs (Level 3) | Contingent consideration
Liabilities:
Total	3.7
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts
Liabilities:
Total	$ 0

Fair Value Measurements - Roll

Fair Value Measurements - Roll Forward (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Beginning balance	$ 2	$ 23.4
Contingent consideration recorded at acquisition	0	0
Fair value adjustments	1.7	0
Payments	0	0
Ending balance	$ 3.7	$ 23.4

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charge	$ 4.3	$ 0
Right of use asset
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charge	12.5
In-process research and development | Mobidiag
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charge	4.3
Intangible Assets, Current	22.4
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	386.3
2029 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	858
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal	$ 1,200
2028 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate	4.625%
2029 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate	3.25%

Business Combination - Narrativ

Business Combination - Narrative (Details) - USD ($) $ in Millions				3 Months Ended
	Jul. 03, 2023	Apr. 03, 2023	Aug. 23, 2020	Dec. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Contingent consideration - fair value adjustment				$ 1.7	$ 0
JW Medical
Business Acquisition [Line Items]
Consideration transferred	$ 6.7
JW Medical | Customer Relationships
Business Acquisition [Line Items]
Intangible assets useful life		5 years
Normedi
Business Acquisition [Line Items]
Consideration transferred		$ 7.7
Contingent consideration		1.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships		$ 3
Normedi | Customer Relationships
Business Acquisition [Line Items]
Intangible assets useful life		5 years
Acessa Health
Business Acquisition [Line Items]
Contingent consideration			$ 81.8	$ 2.6
Annual incremental revenue growth period			3 years

Strategic Investment (Details)

Strategic Investment (Details) - Maverix Medical LLC $ in Millions	Nov. 13, 2023 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 24.5
Equity Method Investment, Ownership Percentage	45%

Disposition - Additional Inform

Disposition - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended
	Sep. 28, 2023	Dec. 30, 2023	Dec. 31, 2022	Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset impairment charge		$ 4.3	$ 0
Disposed of by Sale | SSI Ultrasound Imaging Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales price	$ 1.9
Cash Divested from Deconsolidation	33.2
Intangible asset impairment charge		$ 51.7
Disposal Group, Including Discontinued Operation, Other Assets	$ 50.6			$ 50.6

Disposition - Schedule of Dispo

Disposition - Schedule of Disposition Related Income Statement Information (Details) - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023	Sep. 28, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets	$ 0	$ 11.9
SSI Ultrasound Imaging Business | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash		33.2	$ 33.2
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net			4.5
Disposal Group, Including Discontinued Operation, Inventory			16.2
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets			8.6
Disposal Group, Including Discontinued Operation, Other Assets		$ (50.6)	(50.6)
Disposal Group, Including Discontinued Operation, Assets			11.9
Disposal Group, Including Discontinued Operation, Accounts Payable			3.1
Disposal Group, Including Discontinued Operation, Accrued Liabilities			5.1
Disposal Group, Including Discontinued Operation, Liabilities			$ 8.2

Trade Receivables and Allowan_3

Trade Receivables and Allowance for Credit Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 38.5	$ 37.7
Credit Loss	4.9	1.2
Write-offs, Payments and Foreign Exchange	(0.3)	0.2
Balance at End of Period	$ 43.1	$ 39.1

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Diagnostics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring and Related Cost, Accelerated Depreciation	$ 7.2
Other Asset Impairment Charges	12.5
Severance Costs	1.8
Restructuring and related cost, expected cost minimum	4
Restructuring and related cost, expected cost maximum	8
Danbury closure
Restructuring Costs [Abstract]
Restructuring and Related Cost, Expected Cost	5.9
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Severance Costs	0.5	$ 0.7
Restructuring and Related Cost, Expected Cost	5.9
Facility restoration costs	$ 0.5

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023
Debt Instrument [Line Items]
Current portion of long-term debt	$ 37.4	$ 287
Total long-term debt obligations	2,522.7	2,531.2
Total debt obligations	2,560.1	2,818.2
Term Loan
Debt Instrument [Line Items]
Current portion of long-term debt	37.4	287
Long term debt obligations. excluding convertible notes	1,186.4	1,195.6
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	397	396.8
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	$ 939.3	$ 938.8

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022	Aug. 25, 2022	Sep. 27, 2021
Interest Rate Swap, Agreement One
Debt Instrument [Line Items]
Derivative notional amount	$ 1,000
Variable interest rate	1.23%
Interest Rate Swap, Agreement Two
Debt Instrument [Line Items]
Derivative notional amount	$ 500
Variable interest rate	3.46%
Interest Rate Swap
Debt Instrument [Line Items]
Derivative notional amount			$ 1,000
Variable interest rate			1.23%
Proceeds from Derivative Instrument, Financing Activities	$ 9.7	$ 6.6
Secured Term Loan | 2021 Term Loan
Debt Instrument [Line Items]
Senior notes, face amount	1,200			$ 1,500
Repayments of Debt	250
Revolver | 2021 Revolver
Debt Instrument [Line Items]
Revolving credit facility borrowings				$ 2,000
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Senior notes, face amount	$ 400
Stated interest rate	4.625%
Senior Notes | 2029 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	3.25%
Senior notes	$ 950

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - Credit Agreement - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Interest expense	$ 22.6	$ 20.4
Weighted average interest rate	6.44%	4.63%
Interest rate at end of period	6.46%	5.43%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - Senior Notes - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
2028 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.625%
Interest expense	$ 4.8	$ 5.2
2029 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	3.25%
Interest expense	$ 8.2	8.9
Total
Line of Credit Facility [Line Items]
Interest expense	$ 13	$ 14.1

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - USD ($) $ in Millions	Dec. 30, 2023	Mar. 23, 2023	Aug. 25, 2022
Interest rate swap
Derivative [Line Items]
Derivative notional amount			$ 1,000
Variable interest rate			1.23%
Interest rate swap at fair value	$ 0
Forward Contracts
Derivative [Line Items]
Notational Amount	282.3
Interest Rate Swap, 2023
Derivative [Line Items]
Derivative notional amount		$ 500
Variable interest rate		3.46%
Interest rate swap at fair value	$ 8.2
Interest Rate Swap, 2024
Derivative [Line Items]
Derivative notional amount		$ 500
Variable interest rate		2.98%

Derivatives - Schedule Of Chang

Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ (11.2)	$ (24.7)
Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	1.3	(2.6)
Amount of unrealized gain (loss) recognized in income	(12.5)	(22.1)
Forward foreign currency contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	1.3	(2.4)
Amount of unrealized gain (loss) recognized in income	(12.5)	(13.8)
Foreign currency option contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0	(0.2)
Amount of unrealized gain (loss) recognized in income	$ 0	$ (8.3)

Derivatives - Fair Value of Der

Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023
Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 0
Derivative instruments designated as a cash flow hedge | Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Subject to Master Netting Arrangement, before Offset	8.2	$ 26.9
Derivative instruments designated as a cash flow hedge | Interest rate swap | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	6	16.2
Derivative instruments designated as a cash flow hedge | Interest rate swap | Other assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	2.2	10.7
Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Subject to Master Netting Arrangement, before Offset	0	8.4
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 0	8.4
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value		$ 0

Derivatives - Gain (Loss) on Fa

Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Amount of (loss) gain recognized in other comprehensive income, net of taxes:	$ (14.2)	$ (2.9)
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of (loss) gain recognized in other comprehensive income, net of taxes:	$ (14.2)	$ (2.9)

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	238,627	247,319
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units	1,587	1,962
Diluted weighted average common shares outstanding	240,214	249,281
Outstanding Stock Options and stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	2,046	1,631

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 28.7	$ 20.5
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.8	2.9
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3.2	3.4
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3.2	3.3
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 19.5	$ 10.9

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0.5	0.5
Weighted-average exercise prices (in dollars per share)	$ 71.93	$ 74.26
Share-based compensation, stock options outstanding (in shares)	4.5
Weighted-average exercise price of options outstanding (in dollars per share)	$ 54.20
Unrecognized compensation expense	$ 17.7
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 3 months 18 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.7	0.6
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.90	$ 74.30
Unrecognized compensation expense	$ 86.7
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.92	$ 74.35
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.92	$ 74.35
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
Market Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 88.06	$ 97.91
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
RSU, PSU, MSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	1.7

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	4.40%	4.30%
Expected volatility	33.40%	33.90%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days
Dividend yield	$ 0	$ 0
Weighted average fair value of options granted	$ 24.93	$ 25.81

Other Balance Sheet Informati_3

Other Balance Sheet Information - Inventories (Detail) - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 264.2	$ 238.6
Work-in-process	60.2	66.3
Finished goods	309.2	312.7
Inventories	$ 633.6	$ 617.6

Other Balance Sheet Informati_4

Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 380.6	$ 380
Equipment under customer usage agreements	520.6	508.1
Building and improvements	240.6	230
Leasehold improvements	46	44.4
Land	41.2	41.1
Furniture and fixtures	19.9	19.2
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	8.5	8.2
Property, plant and equipment, gross	1,257.4	1,231
Less – accumulated depreciation and amortization	(730.4)	(714)
Property, plant and equipment, net	$ 527	$ 517

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Dec. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2023 Segment
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment			4
Revenues	$ 1,013,100,000	$ 1,074,200,000
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 1,013.1	$ 1,074.2
Income (loss) from operations	198.2	262.4
Depreciation and amortization	88.4	85.9
Capital expenditures	38	29.1
Identifiable assets	8,469.5		$ 9,139.3
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	447.8	559.3
Income (loss) from operations	49.4	151.1
Depreciation and amortization	65.9	59.9
Capital expenditures	24.2	15.9
Identifiable assets	2,570.1		2,596.4
Breast Health
Segment Reporting Information [Line Items]
Total revenues	377.7	334.2
Income (loss) from operations	102.2	60.5
Depreciation and amortization	10.3	13.6
Capital expenditures	9.3	7.2
Identifiable assets	1,234.1		1,170.1
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	162.2	154.1
Income (loss) from operations	43.2	48.8
Depreciation and amortization	12	12.3
Capital expenditures	4.2	3.9
Identifiable assets	1,450.1		1,455.4
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	25.4	26.6
Income (loss) from operations	3.4	2
Depreciation and amortization	0.2	0.1
Capital expenditures	0.1	0.1
Identifiable assets	30.3		33.7
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	0.2	$ 2
Identifiable assets	$ 3,184.9		$ 3,883.7

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Schedule Of Geographical Segments [Line Items]
Revenues	100%	100%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	74.40%	76.70%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	14.10%	13.70%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	6.30%	5.90%
Rest of World
Schedule Of Geographical Segments [Line Items]
Revenues	5.20%	3.70%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Company's effective tax rate	28.90%	21.60%
Provision (benefit) for income taxes	$ (55.2)	$ 51.7
Foreign Tax Authority
Income Tax Contingency [Line Items]
Provision (benefit) for income taxes	$ 107.2

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 30, 2023	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,352.1	$ 5,342
Accumulated Amortization	4,519.4	4,453.4
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,419.7	4,411
Accumulated Amortization	3,698.9	3,649.5
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	22.4	25.7
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	602.6	600
Accumulated Amortization	559.6	550.6
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	254.1	253.6
Accumulated Amortization	219	212.8
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,298.8	5,290.3
Accumulated Amortization	4,477.5	4,412.9
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	24.9	24
Accumulated Amortization	18.7	17.8
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	28.4	27.7
Accumulated Amortization	$ 23.2	$ 22.7

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Dec. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2024	$ 151.5
Fiscal 2025	188.5
Fiscal 2026	158.6
Fiscal 2027	71.5
Fiscal 2028	$ 68.5

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible asset	$ 4.3	$ 0
Mobidiag
Indefinite-Lived Intangible Assets [Line Items]
Accelerated amortization	7.3
In-process research and development | Mobidiag
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible asset	4.3
Intangible Assets, Current	$ 22.4

Product Warranties - Product Wa

Product Warranties - Product Warranty Activity (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 8.3	$ 8
Provisions	2.9	2.6
Settlements/ Adjustments	(2.1)	(2.2)
Balance at End of Period	$ 9.1	$ 8.4

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 5,016.9
Other comprehensive income (loss) before reclassifications	28.8	$ 110.9
Ending balance	4,653.8
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(147.6)	(238.2)
Ending balance	(118.8)	(127.3)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(168)	(267.2)
Other comprehensive income (loss) before reclassifications	43	113.8
Ending balance	(125)	(153.4)
Pension Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	0.3	(0.3)
Other comprehensive income (loss) before reclassifications	0	0
Ending balance	0.3	(0.3)
Interest Rate Swap | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	20.1	29.3
Other comprehensive income (loss) before reclassifications	(14.2)	(2.9)
Ending balance	$ 5.9	$ 26.4

Share Repurchase Share repurcha

Share Repurchase Share repurchase (Details) - USD ($)		3 Months Ended
	Nov. 15, 2023	Dec. 30, 2023	Dec. 31, 2022	Nov. 06, 2023	Sep. 23, 2022
share repurchase plan [Line Items]
Stock Repurchased During Period, Value		$ 150,000,000	$ 100,000,000
Accelerated share repurchase agreement				$ 500,000,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt	$ 500,000,000
Repurchase of common stock (in shares)	5,600,000
Percentage of share repurchase program	80%
September 22, 2022
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount					$ 1,000,000,000
Stock Repurchased During Period, Shares		2,200,000	1,500,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 348,600,000
December 11, 2020
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount		$ 1,000,000,000